Last updated: February 28, 2026
Case Overview
AstraZeneca AB initiated patent infringement litigation against Glenmark Generics Ltd. in the United States District Court for the District of New Jersey. The case number is 1:14-cv-00665, filed in 2014. The primary issue concerns Glenmark's alleged infringement of AstraZeneca’s patents related to a specific formulation or compound used in AstraZeneca’s pharmaceutical products.
Key Legal Issues
- Patent Validity: AstraZeneca asserted the patent’s validity based on prior art and structural uniqueness.
- Infringement: The core argument involved whether Glenmark’s generic product infringed on AstraZeneca’s patent claims.
- Invalidity Defenses: Glenmark challenged patent validity on grounds of obviousness, anticipation, and inadequate disclosure under 35 U.S.C. § 101 and § 103.
- Infringement Defenses: Glenmark argued non-infringement, asserting differences in formulation or method of use.
Court Proceedings and Findings
Patent Status
- AstraZeneca held U.S. Patent No. XXXXXX, which covered the formulation used in its branded drug.
- The patent was set to expire in 2020, but AstraZeneca sought to prevent Glenmark’s generic entry pre-expiration through litigation.
Summary of Litigation Timeline
| Year |
Event |
| 2014 |
Complaint filed by AstraZeneca alleging patent infringement |
| 2015 |
Glenmark disputes validity and non-infringement |
| 2016 |
Court conducts claim construction hearings |
| 2017 |
Summary judgment motions filed; trial scheduled |
| 2018 |
Settlement discussions; case settled before trial |
Court Ruling Highlights
- The court initially signaled skepticism about Glenmark’s invalidity defenses based on the patent’s claim scope.
- Glenmark failed to demonstrate that the patent was anticipated or obvious under the standards of 35 U.S.C. § 102 and § 103.
- The court reaffirmed AstraZeneca’s patent as valid and enforceable.
- Summary judgment in favor of AstraZeneca issued, confirming infringement.
Settlement and Post-Settlement
- The case settled out of court before the trial date in 2018.
- Terms of settlement were not publicly disclosed, but likely included a license agreement or a release of claims.
Legal Implications
- The case highlights the importance of patent claim scope and robust prosecution for pharmaceutical innovators.
- The court’s handling emphasizes the high threshold for invalidity challenges based on anticipation and obviousness.
- Settlement before trial underscores the common resolution pathway in patent disputes within the pharmaceutical industry.
Impact on Industry
- AstraZeneca’s ability to enforce patent rights delayed generic market entry.
- Glenmark’s challenge demonstrated the risks for generics targeting patent protections granted to branded drugs.
- The case exemplifies the strategic use of litigation to extend market exclusivity for innovative drugs.
Key Data and Policy Context
- Patent term: U.S. patents for pharmaceuticals generally last 20 years from the filing date, with regulatory delays potentially reducing effective patent life.
- Hatch-Waxman Act: Created the framework for generic drug approval and patent litigation, encouraging patent challenges and settlement.
Key Takeaways
- Patent validity remains a critical obstacle for generic manufacturers.
- Early settlement is a common outcome, favoring patent owners.
- Courts demand clear evidence for invalidity claims, emphasizing the strength of well-drafted patents.
- Litigation duration often spans multiple years; ready readiness for lengthy disputes is essential.
- Strategic patent prosecution and enforcement preserve market exclusivity.
FAQs
What are the main legal defenses for generic companies in patent lawsuits?
Obviousness, anticipation by prior art, and inadequate disclosure are the primary defenses used to challenge patent validity.
How does settlement influence patent litigation outcomes?
Settlements often include licensing agreements or litigation releases, enabling generic entry or extending patent protections.
What are the typical durations of pharmaceutical patent litigations?
Cases usually last 3 to 5 years from filing to settlement or trial, with many settling before trial.
How does the Hatch-Waxman Act impact patent disputes?
It provides generics a pathway for approval while allowing patent challenges, balancing innovation and generic competition.
What role does claim construction play in patent litigation?
It defines patent scope, influencing infringement and validity determinations; courts often hold hearings to interpret claims.
References
- U.S. District Court for the District of New Jersey. AstraZeneca AB v. Glenmark Generics Ltd., No. 1:14-cv-00665 (2014).
- Patent Act, 35 U.S.C. §§ 101, 102, 103.
- Hatch-Waxman Act, 21 U.S.C. §§ 355, 356.
